Safety Concerns Make Bayer Unblind Prostate Cancer Trial of Xofigo Combination

Safety Concerns Make Bayer Unblind Prostate Cancer Trial of Xofigo Combination
An Independent Data Monitoring Committee has asked Bayer to unblind a Phase 3 clinical trial of a Xofigo (radium-223)-based therapy for prostate cancer after data indicated more bone fractures in study participants. The study randomly assigned prostate cancer patients to treatment with Xofigo or a placebo — both given in combination with Zytiga (abiraterone acetate) and

Knowledge is power when living with prostate cancer.

Get access to the web’s leading Prostate Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *